Oncology News | pharmaphorum

News

Breast cancer assayed with anti HER-2 antibody

EU starts review of first-line Enhertu for breast cancer

EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.

News

HCP with a small pile of pills in their palm

NICE relents, ending postcode access to prostate cancer drug

Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.

News

J&J builds case for earlier Tecvayli use in multiple myeloma

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

News

Perlmutter's Eikon follows the IPO trail

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

EU starts review of first-line Enhertu for breast cancer

NICE relents, ending postcode access to prostate cancer drug

J&J builds case for earlier Tecvayli use in multiple myeloma

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

Perlmutter's Eikon follows the IPO trail

Now Iktos teams up with Pierre Fabre in oncology

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks